FDA panel: Some birth control pills should carry stronger warning labels

An FDA panel decided Thursday that two popular birth control pills should come with stronger warning labels about the possibility of blood clots.

The New York Times: More Detail On Risk Urged For A Contraceptive Label
Labels on the popular birth control pills Yaz and Yasmin should be strengthened to include more information about the possibility that the pills could lead to greater risk of blood clots in women, an advisory committee to the Food and Drug Administration said on Thursday. The panel, which voted 21 to 5 in favor of changing the labels, stopped short of recommending that they warn that the drugs are more likely than other contraceptive pills to cause blood clots (Belluck, 12/8).

The Washington Post: Stronger Warnings Urged On Safety Of New Birth Control Pills
After a day-long hearing, two Food and Drug Administration advisory committees, meeting together, voted 15 to 11 that the benefits of the pills in preventing unwanted pregnancies outweighed the risks. But the panels voted 21 to 5 that the current labels fail to adequately warn of the dangers, and they urged the agency to require stronger admonitions (Stein, 12/8).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
More mobile clinics are bringing long-acting birth control to rural areas